As global regulatory frameworks continue to evolve, I believe one of the biggest opportunities for MedTech companies is learning how to strategically leverage prior approvals across markets.
In our recent RegDesk webinar, Faster Global Submissions: Using Prior Approvals to Your Advantage, I discussed how reliance and recognition pathways are reshaping global medical device submissions and what regulatory teams should understand before building international market entry strategies around them.
Watch the Full Webinar Replay
One of the most important points I emphasized during the session is that reliance does not mean automatic approval.
Many manufacturers assume that FDA clearance or CE MDR certification will translate directly into faster approvals everywhere else. In practice, every country still maintains its own regulatory authority, documentation expectations, and review process. Prior approvals can absolutely support global expansion strategies, but they must be applied within a country-specific regulatory framework.
As more regulatory authorities adopt reliance-based models, regulatory teams have an opportunity to reduce duplication, improve submission efficiency, and accelerate market access. At the same time, the operational complexity behind those strategies is often underestimated.
Why Reliance Pathways Matter More Than Ever
Over the last several years, we have seen regulators globally place increasing focus on reliance and recognition frameworks as a way to improve review efficiency while maintaining patient safety standards.
Countries across Latin America, the Middle East, Africa, and Asia Pacific are increasingly incorporating prior approvals into their regulatory evaluation processes. In many cases, regulators may leverage FDA approvals, CE MDR certifications, Health Canada licenses, TGA approvals, or other reference market decisions as part of their review pathway.
However, the structure of these pathways varies significantly by country.
Some markets offer recognition pathways with limited additional review requirements. Others apply abridged review models or verification pathways that still require localized documentation, labeling, or administrative review.
This is where many global regulatory strategies begin to break down. Teams often underestimate how much local adaptation is still required even when leveraging prior approvals.
One of the Biggest Misconceptions About Reliance
One of the most common misconceptions I see is treating reliance as a shortcut rather than a structured regulatory strategy.
Reliance can help accelerate portions of the submission process, but it does not eliminate the need for:
- Country-specific documentation
- Local representatives
- Labeling adaptation
- Translation requirements
- Legalization requirements
- Post-market obligations
- Ongoing regulatory monitoring
High-performing regulatory teams treat reliance pathways as one component within a broader global submission strategy rather than the entire strategy itself.
Key Considerations for Global Submission Planning
During the webinar, I shared several areas regulatory teams should evaluate when planning multi-market submissions.
Sequence Markets Strategically
The order in which approvals are obtained matters. Strong global strategies are often built around identifying which markets can serve as effective reference approvals for future submissions.
Understand Country-Specific Expectations Early
Even when leveraging prior approvals, local requirements still drive the success of the submission. Teams that validate expectations early avoid significant downstream delays. Read more about reliance pathways in CIS countries, Sri Lanka, South Africa.
Maintain Documentation Consistency
Small inconsistencies across product names, intended use statements, labeling, or technical documentation can create avoidable review cycles across multiple markets.
Monitor Regulatory Changes Continuously
Reliance pathways continue to evolve globally. Regulatory intelligence cannot be treated as a one-time activity.
Organizations need ongoing visibility into:
- Which markets accept prior approvals
- What level of reliance is permitted
- Which documentation can be leveraged
- What local adaptations remain required
- How changing regulations affect active submissions
The Operational Side of Reliance Strategies
One of the themes I focused on throughout the webinar is that successful global submissions are not only about regulatory knowledge. They are also about operational coordination.
As companies expand across more markets, fragmented tracking systems, disconnected workflows, and inconsistent documentation management become significant obstacles to efficient execution.
This is where connected regulatory intelligence and submission management systems become increasingly important. Regulatory teams need visibility across markets, reusable submission content, and centralized tracking to effectively manage complex international strategies.
How RegDesk Supports Global Submission Strategies
As reliance and recognition pathways continue to expand globally the challenge becomes coordinating execution across multiple evolving markets while maintaining consistency, visibility, and speed.
At RegDesk, we help MedTech companies centralize regulatory intelligence, manage global submissions, and maintain real-time visibility across products, countries, and regulatory activities in one connected platform.
For organizations leveraging prior approvals as part of their market access strategy, RegDesk supports more coordinated execution through centralized submission tracking, reusable documentation, continuous regulatory monitoring, and AI-powered workflows that help teams reduce duplication and improve submission efficiency across markets.
As discussed throughout this webinar, successful global expansion depends not only on regulatory expertise, but on the ability to operationalize that expertise consistently across every stage of the submission lifecycle.
